Recombinant tumor necrosis factor for superficial bladder tumors.

Twenty patients with histologically documented superficial bladder cancer (Ta, T1, Tis) were treated with intravesical administration of TNF 400-1800 micrograms. Of 18 patients with a marker lesion, 2 obtained a complete response for 8+ and 18 months. Two had a partial response and were given other intravesical therapies after 5 and 7 months. No or minimal systemic absorption of TNF was observed and documented in 4 of 20 patients by pharmacokinetic studies, and no patients developed antibodies to intravesically administered TNF. TNF was well tolerated in doses up to 1800 micrograms. No systemic or local side effects were observed. Modest activity was attained with intravesical TNF, even in pretreated patients.

[1]  G. Hahn,et al.  Mechanism of Antitumor Activity of Tumor Necrosis Factor α With Hyperthermia in a Tumor Necrosis Factor α-Resistant Tumor , 1990 .

[2]  J. Gerdes,et al.  Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. , 1990, The Journal of urology.

[3]  J. Hannigan,et al.  Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Old.  Tumor necrosis factor. , 1988, Scientific American.

[5]  J. Gabrilove,et al.  Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Newell,et al.  In pursuit of evidence based integrated care , 1987, British Journal of Cancer.

[7]  A. Cockett,et al.  Effect of intravesical administration of tumor necrosis serum and human recombinant tumor necrosis factor on a murine bladder tumor. , 1987, The Journal of urology.

[8]  D. Lamm.  Bacillus Calmette-Guerin immunotherapy for bladder cancer. , 1985, The Journal of urology.

[9]  Robert C. Leif,et al.  Convention on nomenclature for DNA cytometry , 1984 .

[10]  M. Soloway.  Rationale for intensive intravesical chemotherapy for superficial bladder cancer. , 1980, The Journal of urology.

[11]  Lloyd J. Old,et al.  Effect of tumour necrosis factor on cultured human melanoma cells , 1975, Nature.

[12]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.